Passage Bio Stock Revenue
| PASG Stock | USD 5.74 0.68 10.59% |
Fundamental analysis of Passage Bio allows traders to better anticipate movements in Passage Bio's stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year |
Passage | Revenue | Build AI portfolio with Passage Stock |
Passage Bio Company Revenue Analysis
Passage Bio's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of Passage
Projected quarterly revenue analysis of Passage Bio provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Passage Bio match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Passage Bio's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Passage Bio reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
Passage Bio is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 73.11 Million. Passage Bio adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.Passage Bio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Passage Bio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Passage Bio's managers, analysts, and investors.Environmental | Governance | Social |
Passage Bio Institutional Holders
Institutional Holdings refers to the ownership stake in Passage Bio that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Passage Bio's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Passage Bio's value.| Shares | Fiduciary Trust Co | 2025-03-31 | 215 K | State Street Corp | 2025-03-31 | 156.8 K | Shay Capital Llc | 2025-03-31 | 146.7 K | Rbf Llc | 2025-03-31 | 142.8 K | Millennium Management Llc | 2025-03-31 | 136.2 K | Northern Trust Corp | 2025-03-31 | 112 K | Simplex Trading, Llc | 2025-03-31 | 82.3 K | Squarepoint Ops Llc | 2025-03-31 | 64.1 K | Two Sigma Investments Llc | 2025-03-31 | 47 K | Orbimed Advisors, Llc | 2025-03-31 | 7 M | Vestal Point Capital Lp | 2025-03-31 | 6.1 M |
Passage Fundamentals
| Return On Equity | -0.84 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (18.44 M) | ||||
| Shares Outstanding | 3.12 M | ||||
| Shares Owned By Insiders | 0.20 % | ||||
| Shares Owned By Institutions | 56.03 % | ||||
| Number Of Shares Shorted | 108.28 K | ||||
| Price To Book | 0.42 X | ||||
| EBITDA | (61.69 M) | ||||
| Net Income | (64.77 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 25.48 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 15.03 X | ||||
| Cash Flow From Operations | (47.96 M) | ||||
| Short Ratio | 2.87 X | ||||
| Earnings Per Share | (20.40) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 60 | ||||
| Beta | 1.67 | ||||
| Market Capitalization | 20.03 M | ||||
| Total Asset | 102.41 M | ||||
| Retained Earnings | (659.24 M) | ||||
| Working Capital | 59.45 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
| Net Asset | 102.41 M |
About Passage Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Passage Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Passage Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Passage Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Passage Bio Piotroski F Score and Passage Bio Altman Z Score analysis. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.